259 related articles for article (PubMed ID: 30182192)
1. [Baroreflex activation therapy : Indication and evidence in resistant hypertension and heart failure].
Wallbach M; Koziolek MJ; Wachter R
Internist (Berl); 2018 Oct; 59(10):1011-1020. PubMed ID: 30182192
[TBL] [Abstract][Full Text] [Related]
2. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial.
Bisognano JD; Bakris G; Nadim MK; Sanchez L; Kroon AA; Schafer J; de Leeuw PW; Sica DA
J Am Coll Cardiol; 2011 Aug; 58(7):765-73. PubMed ID: 21816315
[TBL] [Abstract][Full Text] [Related]
3. Electrical carotid baroreceptor stimulation.
Schmidli J; von Allmen RS; Mohaupt MG
Wien Med Wochenschr; 2014 Dec; 164(23-24):508-14. PubMed ID: 25411011
[TBL] [Abstract][Full Text] [Related]
4. Effects of Baroreflex Activation Therapy on Ambulatory Blood Pressure in Patients With Resistant Hypertension.
Wallbach M; Lehnig LY; Schroer C; Lüders S; Böhning E; Müller GA; Wachter R; Koziolek MJ
Hypertension; 2016 Apr; 67(4):701-9. PubMed ID: 26902491
[TBL] [Abstract][Full Text] [Related]
5. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial.
Bakris GL; Nadim MK; Haller H; Lovett EG; Schafer JE; Bisognano JD
J Am Soc Hypertens; 2012; 6(2):152-8. PubMed ID: 22341199
[TBL] [Abstract][Full Text] [Related]
6. Safety profile of baroreflex activation therapy (NEO) in patients with resistant hypertension.
Wallbach M; Böhning E; Lehnig LY; Schroer C; Müller GA; Wachter R; Lüders S; Zenker D; Koziolek MJ
J Hypertens; 2018 Aug; 36(8):1762-1769. PubMed ID: 29677053
[TBL] [Abstract][Full Text] [Related]
7. Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction.
Zile MR; Lindenfeld J; Weaver FA; Zannad F; Galle E; Rogers T; Abraham WT
J Am Coll Cardiol; 2020 Jul; 76(1):1-13. PubMed ID: 32616150
[TBL] [Abstract][Full Text] [Related]
8. [Baroreceptor activation therapy for therapy-resistant hypertension: indications and patient selection : Recommendations of the BAT consensus group 2017].
Koziolek M; Beige J; Wallbach M; Zenker D; Henning G; Halbach M; Mader N; Mahfoud F; Schlieper G; Schwenger V; Hausberg M; Börgel J; Lodde M; van der Giet M; Müller-Ehmsen J; Passauer J; Parmentier S; Lüders S; Krämer BK; Büttner S; Limbourg F; Jordan J; Vonend O; Predel HG; Reuter H
Internist (Berl); 2017 Oct; 58(10):1114-1123. PubMed ID: 28835975
[TBL] [Abstract][Full Text] [Related]
9. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial.
Hoppe UC; Brandt MC; Wachter R; Beige J; Rump LC; Kroon AA; Cates AW; Lovett EG; Haller H
J Am Soc Hypertens; 2012; 6(4):270-6. PubMed ID: 22694986
[TBL] [Abstract][Full Text] [Related]
10. Baroreceptor stimulation for resistant hypertension: first implantation in France and literature review.
Courand PY; Feugier P; Workineh S; Harbaoui B; Bricca G; Lantelme P
Arch Cardiovasc Dis; 2014 Dec; 107(12):690-6. PubMed ID: 25445751
[TBL] [Abstract][Full Text] [Related]
11. Restoration of normal sympathetic neural function in heart failure following baroreflex activation therapy: final 43-month study report.
Dell'Oro R; Gronda E; Seravalle G; Costantino G; Alberti L; Baronio B; Staine T; Vanoli E; Mancia G; Grassi G
J Hypertens; 2017 Dec; 35(12):2532-2536. PubMed ID: 28816745
[TBL] [Abstract][Full Text] [Related]
12. Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction.
Abraham WT; Zile MR; Weaver FA; Butter C; Ducharme A; Halbach M; Klug D; Lovett EG; Müller-Ehmsen J; Schafer JE; Senni M; Swarup V; Wachter R; Little WC
JACC Heart Fail; 2015 Jun; 3(6):487-496. PubMed ID: 25982108
[TBL] [Abstract][Full Text] [Related]
13. An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems.
Wachter R; Halbach M; Bakris GL; Bisognano JD; Haller H; Beige J; Kroon AA; Nadim MK; Lovett EG; Schafer JE; de Leeuw PW
J Am Soc Hypertens; 2017 Feb; 11(2):81-91. PubMed ID: 28065708
[TBL] [Abstract][Full Text] [Related]
14. Bilateral or unilateral stimulation for baroreflex activation therapy.
de Leeuw PW; Alnima T; Lovett E; Sica D; Bisognano J; Haller H; Kroon AA
Hypertension; 2015 Jan; 65(1):187-92. PubMed ID: 25331845
[TBL] [Abstract][Full Text] [Related]
15. The effects of baroreflex activation therapy on blood pressure and sympathetic function in patients with refractory hypertension: the rationale and design of the Nordic BAT study.
Gordin D; Fadl Elmula FEM; Andersson B; Gottsäter A; Elf J; Kahan T; Christensen KL; Vikatmaa P; Vikatmaa L; Bastholm Olesen T; Groop PH; Olsen MH; Tikkanen I;
Blood Press; 2017 Oct; 26(5):294-302. PubMed ID: 28595464
[TBL] [Abstract][Full Text] [Related]
16. Baroreflex activation therapy in patients with heart failure with reduced ejection fraction: a single-centre experience.
Blanco C; Madej T; Mangner N; Hommel J; Grimm S; Knaut M; Linke A; Winzer EB
ESC Heart Fail; 2023 Dec; 10(6):3373-3384. PubMed ID: 37667319
[TBL] [Abstract][Full Text] [Related]
17. Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease.
Halbach M; Abraham WT; Butter C; Ducharme A; Klug D; Little WC; Reuter H; Schafer JE; Senni M; Swarup V; Wachter R; Weaver FA; Wilks SJ; Zile MR; Müller-Ehmsen J
Int J Cardiol; 2018 Sep; 266():187-192. PubMed ID: 29705650
[TBL] [Abstract][Full Text] [Related]
18. Effects of chronic carotid baroreceptor activation on arterial stiffness in severe heart failure.
Gronda E; Brambilla G; Seravalle G; Maloberti A; Cairo M; Costantino G; Lovett E; Vanoli E; Mancia G; Grassi G
Clin Res Cardiol; 2016 Oct; 105(10):838-46. PubMed ID: 27120329
[TBL] [Abstract][Full Text] [Related]
19. Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials.
Coats AJS; Abraham WT; Zile MR; Lindenfeld JA; Weaver FA; Fudim M; Bauersachs J; Duval S; Galle E; Zannad F
Eur J Heart Fail; 2022 Sep; 24(9):1665-1673. PubMed ID: 35713888
[TBL] [Abstract][Full Text] [Related]
20. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy.
Zile MR; Abraham WT; Weaver FA; Butter C; Ducharme A; Halbach M; Klug D; Lovett EG; Müller-Ehmsen J; Schafer JE; Senni M; Swarup V; Wachter R; Little WC
Eur J Heart Fail; 2015 Oct; 17(10):1066-74. PubMed ID: 26011593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
